EORTC QoL FinTox

cross-entity / Basket
General
Register and supportive Studies
The financial impact of cancer on the individual patient is often characterised as an objective and a subjective financial burden. The objective financial burden gives no information on how the patient himself perceives the financial impact and the consequences on his life; this view is provided by the subjective financial burden, which describes the impact and consequences of the objective costs on the patient. This often results in material consequences, psychological effects, or behavioural changes, which then are expressed as a “financial toxicity”. The currently existing tools are either only narrowly validated, are generic economic tools, are restricted to a certain health care system, are restricted to a specific cancer site, or do not cover all relevant domains of financial toxicity. The aim of this Phase I study is to develop a list of issues related to financial toxicity in cancer patients.
The aim of this study is to develop a quality of life questionnaire for patients that assesses the financial consequences of cancer and its impact on the patient.